RT Journal Article
SR Electronic
T1 Development and performance of a population-based risk stratification model for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.25.21257783
DO 10.1101/2021.05.25.21257783
A1 Emili Vela
A1 Gerard Carot-Sans
A1 Montse Clèries
A1 David Monterde
A1 Xènia Acebes
A1 Adrià Comella
A1 Luís García Eroles
A1 Marc Coca
A1 Damià Valero-Bover
A1 Jordi Piera-Jiménez
A1 Pol Pérez Sust
YR 2021
UL http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257783.abstract
AB The shortage of recently approved vaccines against the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has highlighted the need for evidence-based tools to prioritize healthcare resources for people at higher risk of severe coronavirus disease 2019 (COVID-19). Current evidence indicates that age is far from accurate in identifying the risk of severe illness; furthermore, the count of individual risk factors has limited applicability to population-based “stratify-and-shield” strategies. We developed a COVID-19 risk stratification system that allows allocating people into four mutually-exclusive risk categories based on multivariate models for hospital admissions, transfer to intensive care unit (ICU), and mortality among the general population. The model was developed using clinical, hospital, and epidemiological data from the entire population of Catalonia (North-East Spain; 7.5 million people) and validated using an independent dataset of 218,329 individuals with PCR-confirmed COVID-19, who were infected after developing the model. This showed high discrimination capacity, with an area under the curve of the receiving operating characteristics of 0.85 (95% CI 0.85 – 0.85) for hospital admissions, 0.86 (0.86 – 0.97) for ICU transfers, and 0.96 (0.96 – 0.96) for deaths. Our results provide clinicians and policymakers with an evidence-based tool for prioritizing COVID-19 healthcare resources other population groups aside from those with higher exposure to SARS-CoV-2 and frontline workers.Competing Interest StatementEM, MC, and DM are the developers of the GMA tool used to develop the stratification risk model. The authors declare no support from any for profit organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, nor other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNot applicable (retrospective analysis)Funding StatementThis study did not receive specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Independent Ethics Committee of the IDIAP Jordi Gol (Spain), which waived the need for written informed consent (21/043-PCV)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly accessible but are available from the corresponding author upon reasonable request.